

## Special Issue

# Anti-cancer Vaccines, Adoptive Cell Therapies and Immune-Checkpoint Inhibitors: A Novel Arsenal against Cancer

### Message from the Guest Editors

Recent discoveries in cancer immunology have resulted in the incorporation of immunotherapeutic strategies for the treatment of various solid and hematologic malignancies. Immunotherapy is currently deemed to be the best way to improve prognosis for cancer patients in the near future. In this Special Issue, we provide an overview of clinical outcomes of immunotherapy in patients with advanced and/or metastatic malignancies as well as cover major clinical and scientific hurdles of cancer immunotherapy. Original research articles and reviews are welcome (note that systematic reviews must follow PRISMA guidelines). Research areas may include (but are not limited to) the following: anticancer vaccines, cancer immunotherapy, adoptive cellular therapy, T cell research, novel checkpoint inhibitors, NK cell therapy, systematic reviews with meta-analysis.

### Guest Editors

Dr. Dmitrii Shek

Blacktown Clinical School, Western Sydney University, Marcel Crescent, Sydney, NSW 2148, Australia

Prof. Dr. Golo Ahlenstiel

Blacktown Clinical School, Western Sydney University, Marcel Crescent, Sydney, NSW 2148, Australia

### Deadline for manuscript submissions

closed (5 December 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/163478](https://mdpi.com/si/163478)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).